Articles by ‘Claus Andersen’

After more than 4 years of debate in the UK since the referendum and after years of negotiation with the EU about, first, a withdrawal agreement and then an agreement setting out how the future trade in some areas between the EU and the UK should work, the UK-EU Trade and Cooperation Agreement was finally signed yesterday by the EU and the UK governments.

With the post-Brexit transition period ending in 31 December 2020 and talks between the EU and UK about a Free Trade Agreement (“FTA”) continuing, businesses need to continue to prepare for the key challenges ahead.

On 9 November 2020 I had the pleasure of speaking at the 13th Annual European GRC and GDPR compliance conference hosted by Copenhagen Compliance.

The UK BioIndustry Association, BIA, has just released its investment report for the period 1 June to 31 August 2020.

With the end of the Brexit transition period fast approaching it is becoming more and more urgent for businesses in the medical sector to prepare for the transition period coming to an end. It is a sector, where many of the rules stem from EU regulation, which makes it even more important for businesses to prepare.

As the social, economic, and health impacts of COVID continue to ripple around the globe, it would seem that the UK Biotech sector is weathering the storm. But despite its robust response, there are warming signs that should not be ignored.

There has been much publicity about the various support measures and schemes put in place to support businesses affected by COVID-19 such as the Coronavirus Business Interruption Loan Scheme (CBILS) and the Job Retention Scheme. One of the less publicised measures is specific support for UK businesses trading abroad.

In light of the Coronavirus outbreak the Medicines and Healthcare products Regulatory Authority (MHRA), which is the authority which supervises the Medical Device and Pharmaceutical sector, has recently released a series of guidance notes about how the MHRA will deal with certain aspects of the Life Sciences sector during the COVID-19 outbreak.

When you cover Brexit, like I do, you cannot help feeling a bit like the proverbial ‘boy who cried wolf’. Over the past three and a half years, all of us dealing with Brexit in blogs, comments and seminars have said on numerous occasions that “Brexit was coming” – only for it to be delayed, over and over again. However, this time the wolf is real: Brexit is actually coming.

On Thursday 14 November I attended a great event at the offices of Deutsche Bank hosted and organised by the Swedish Chamber of Commerce in London.

The speculation is over. What’s in store for businesses across the UK now?

Recent weeks have in the news been dominated by Brexit, the withdrawal agreement, the suspension of Parliament and in the end the Queen’s speech.